Source comparison
GHRP-2 Acetate vs MK-677: Which GH Secretagogue Works Best?
Research published in the Journal of Clinical Endocrinology & Metabolism found that both GHRP-2 (growth hormone-releasing peptide-2) and MK-677 (ibutamoren) elevate serum GH levels by 200–300% above baseline. But through distinct pathways with meaningfully dif
This comparison does not assign a generated winner or score.
- Research published in the Journal of Clinical Endocrinology & Metabolism found that both GHRP-2 (growth hormone-releasing peptide-2) and MK-677 (ibutamoren) elevate serum GH levels by 200–300% above baseline. But through distinct pathways with meaningfully different pharmacokinetics. GHRP-2 acetate acts as a direct ghrelin receptor agonist with a 30-minute plasma half-life, requiring multiple daily administrations to maintain therapeutic levels. MK-677 functions as a growth hormone secretagogue with a 24-hour half-life, allowing once-daily oral dosing but triggering sustained appetite stimulation that GHRP-2 does not.
- Our team has worked with researchers evaluating both compounds across hundreds of protocols. The choice between GHRP-2 acetate and MK-677 comes down to three variables most comparison guides ignore: injection tolerance, cost per effective dose, and protocol duration.
- What's the practical difference between GHRP-2 acetate and MK-677 for research applications?
- GHRP-2 acetate is a synthetic hexapeptide that stimulates pituitary GH secretion through ghrelin receptor activation, requiring subcutaneous injection 2–3 times daily due to its 30-minute half-life. MK-677 (ibutamoren) is an orally bioavailable non-peptide GH secretagogue with a 24-hour half-life, allowing once-daily dosing but producing more pronounced appetite stimulation and slight prolactin elevation. Both compounds increase IGF-1 levels by 40–90% depending on dose, but MK-677 costs 3–4× more per month at therapeutic doses.
- The standard framing of this comparison. That MK-677 is 'better' because it's oral. Misses the nuance that matters in research contexts. GHRP-2 acetate offers pulse-based GH release that more closely mimics endogenous secretion patterns, while MK-677 produces sustained elevation that may be preferable or problematic depending on study design. This article covers the receptor mechanisms driving those differences, the cost-per-dose reality most suppliers don't disclose, and the administration protocols that determine which compound fits specific research parameters.